Aquestive Therapeutics eases disclosure requirements for stockholder board nominations
AQST•Aquestive Therapeutics adopted bylaw amendments easing disclosure requirements for stockholder board nominations, effective Oct. 15, 2026.
1. Bylaw amendments
The amendments remove disclosure requirements for certain relationships involving nominating stockholders and people acting in concert with nominees or their related parties. The revised “Stockholder Associated Person” definition excludes people acting in concert with nominating stockholders or beneficial owners submitting nominations or proposals.
